1. No HBV or HIV co-infection
MAGELLAN-I Study : ABT ABT-530 in genotype 1 with failure to DAA regimen – Phase II
Design
W12
Randomisation
Open-label
N = 6 *
ABT mg qd + ABT mg qd
SVR12
18-70 years
HCV genotype 1
Failure to DAA regimen
HCV RNA > IU/ml
No cirrhosis
No HBV or HIV co-infection
N = 22
ABT mg qd + ABT mg qd
SVR12
N = 22
ABT mg qd + ABT mg qd
+ RBV 800 mg qd
SVR12
* Low dose arm halted (based on dose-findings results across all genotypes)
Objective
SVR12 (HCV RNA < 25 IU/ml), by ITT
MAGELLAN-I
Poordad F. EASL 2016, Abs. GS11, J Hepatol 2016; 64:S160-1 1

2. Baseline characteristics
MAGELLAN-I Study : ABT ABT-530 in genotype 1 with failure to DAA regimen – Phase II
Baseline characteristics
ABT mg + ABT mg
N = 6
ABT mg + ABT mg
N = 22
ABT mg
+ ABT mg
+ RBV 800 mg
Median age, years 59 56
Female, % 50 18
Race : White , % 67 55 77
Median BMI, kg/m2 27 28
Genotype 1a, % 82 91
Median HCV RNA, log10 IU/ml
6.1
6.6
6.7
Fibrosis stage (%) : F0-F1 / F2 / F3
67 / 17 / 17
50 / 27 / 23
77 / 0 / 23
Prior regimen
PI-experienced, NS5A naïve, n = 25
NS5A-experienced, PI-naïve, n = 8
PI and NS5A-experienced, n = 17
SOF-experienced, n = 16
MAGELLAN-I
Poordad F. EASL 2016, Abs. GS11, J Hepatol 2016; 64:S160-1 2

3. MAGELLAN-I Study : ABT-493 + ABT-530 in genotype 1 with failure to DAA regimen – Phase II
SVR12, ITT 6 22 %
100 86 91 N=
Breakthrough 1
Relapse
Lost to follow-up 2
MAGELLAN-I
Poordad F. EASL 2016, Abs. GS11, J Hepatol 2016; 64:S160-1 3

4. MAGELLAN-I Study : ABT-493 + ABT-530 in genotype 1 with failure to DAA regimen – Phase II
2 virologic failures
Prior DAA regimen(s)
Response
NS3 RAVs
NS5A RVAs
Baseline
Failure
OBV/PTV/r + DSV + RBV
Breakthrough
Y56H
D168A/T
V36M
D168A
M28V
Q30L/R
M28G
Q30S
DCV ; TVR + PR
Relapse
None
Pending
L31M
H58D
SVR12 (ITTm) according to baseline RAVs
No RAVs
N = 6
NS3 RAVs only
N = 15
NS5A RAVs only
N = 10
NS3 & NS5A RAVs
N = 16
SVR12
100%
90%
94%
MAGELLAN-I
Poordad F. EASL 2016, Abs. GS11, J Hepatol 2016; 64:S160-1 4

5. Adverse events and laboratory abnormalities, %
MAGELLAN-I Study : ABT ABT-530 in genotype 1 with failure to DAA regimen – Phase II
Adverse events and laboratory abnormalities, %
ABT mg + ABT mg
N = 6
ABT mg + ABT mg
N = 22
ABT mg
+ ABT mg
+ RBV 800 mg
Any adverse event 83 77 71
Treatment-related serious adverse event
Adverse event leading to discontinuation
Adverse events in > 10% of patients
Headache
Fatigue
Nausea
Insomnia 17 36 18 14 23 27
Laboratory abnormalities, n
ALT grade ≥ 2 / AST grade ≥ 2
Total bilirubin grade 2
Alkaline phosphatase grade ≥ 2
Hemoglobin grade ≥ 2 3
MAGELLAN-I
Poordad F. EASL 2016, Abs. GS11, J Hepatol 2016; 64:S160-1 5

6. MAGELLAN-I Study : ABT-493 + ABT-530 in genotype 1 with failure to DAA regimen – Phase II
Summary
High SVR12 rates after 12 weeks of ABT ABT-530 with only 2 virologic failures in 50 DAA-experienced genotype 1 patients without cirrhosis
Baseline NS3 and/or NS5A RAVs did not impact SVR12
RBV did not increase SVR12 rate
Good tolerability, with mild adverse events
No grade 3 or 4 laboratory abnormalities
No discontinuation due to adverse events
MAGELLAN-I
Poordad F. EASL 2016, Abs. GS11, J Hepatol 2016; 64:S160-1 6